Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models

PURPOSE: Though the efficacy of MEK inhibitors is being investigated in KRAS-mutant colorectal cancers (CRC), early clinical trials of MEK inhibitor monotherapy did not reveal significant antitumor activity. Resistance to MEK inhibitor monotherapy developed through a variety of mechanisms converging...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Michael S., Helms, Timothy L., Feng, Ningping, Gay, Jason, Chang, Qing Edward, Tian, Feng, Wu, Ji Y., Toniatti, Carlo, Heffernan, Timothy P., Powis, Garth, Kwong, Lawrence N., Kopetz, Scott
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129956/
https://www.ncbi.nlm.nih.gov/pubmed/27167191
http://dx.doi.org/10.18632/oncotarget.9153

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129956/
https://www.ncbi.nlm.nih.gov/pubmed/27167191
http://dx.doi.org/10.18632/oncotarget.9153

Ejemplares similares